knowledge -WSS

knowledge

author：fashion 2025-09-14 10:13:27 - browse：8

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Why 40% Americans with Parkinson’s don’t see a neurologist

focus

explore

WSS

Biden's 'march

Immune cells and nerve overgrowth may explain recurring UTI pain

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

First over

Harvard's David Sinclair gets blowback over aging

N.Y. state detects polio case, first in the U.S. since 2013

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

A new study sees potential in DNA sequencing of infants

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Ancient Greek ideas underpin modern concepts of pregnancy

23andMe had bad news about my health. I wish a person had delivered it

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

At least 13 dead in Texas as scorching temps continue

Why 40% Americans with Parkinson’s don’t see a neurologist

United colonoscopy coverage change 'may cost lives,' doctors say

Bulgari apologizes to China for listing Taiwan as a country after online backlash

knowledge

NIH fellows want a pay raise. Will that mean less money for grants?

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Palantir health business leans on meeting customers’ needs

N.Y. state detects polio case, first in the U.S. since 2013

Fetal cell organoids grown from amniotic fluid, study finds

Oak trusses raised to roof of fire

hotspot

focus

explore

hotspot